DrugPatentWatch Database Preview
LYRICA Drug Profile
When do Lyrica patents expire, and when can generic versions of Lyrica launch?
Lyrica is a drug marketed by Pf Prism Cv and is included in three NDAs. There are six patents protecting this drug and six Paragraph IV challenges.
This drug has sixty-eight patent family members in thirty-one countries.
The generic ingredient in LYRICA is pregabalin. There are forty-one drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the pregabalin profile page.
Summary for LYRICA
| International Patents: | 68 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 3 |
| Suppliers / Packagers: | 11 |
| Bulk Api Vendors: | 80 |
| Clinical Trials: | 81 |
| Patent Applications: | 3,863 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LYRICA |
| Drug Sales Revenues: | Drug sales revenues for LYRICA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LYRICA |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for LYRICA |
| DailyMed Link: | LYRICA at DailyMed |
Medical Subject Heading (MeSH) Categories for LYRICA
Synonyms for LYRICA
| (3S)-3-(aminomethyl)-5-methyl hexanoic acid |
| (3S)-3-(aminomethyl)-5-methyl-hexanoic acid |
| (3S)-3-(aminomethyl)-5-methylhexanoic acid |
| (R-)-3-isobutyl GABA |
| (S)-(+)-3-Aminomethyl-5-Methylhexanoic Acid |
| (S)-(+)-4-amino-3-(2-methylpropyl)butanoic acid |
| (S)-3-(Aminomethyl)-5-methylhexanoic acid |
| (S)-3-(Aminomethyl)-5-methylhexanoicacid |
| (S)-3-Aminomethyl-5-methyl-hexanoic acid |
| (S)-3-aminomethyl-5-methylhexanoic acid |
| (S)-3-Isobutyl GABA |
| (S)-Pregabalin |
| 121GE001 |
| 148553-50-8 |
| 3-isobutyl GABA |
| 553P508 |
| 55JG375S6M |
| A808784 |
| AB0074009 |
| AB01563007_01 |
| AB1008692 |
| AC-1158 |
| AC1NUP03 |
| ACN-038395 |
| AJ-08241 |
| AKOS001476611 |
| AKOS005145504 |
| AM20080369 |
| AN-1059 |
| AYXYPKUFHZROOJ-ZETCQYMHSA-N |
| BC634849 |
| BDBM50164279 |
| CAS-148553-50-8 |
| CCG-221247 |
| CHEBI:64356 |
| CHEMBL1059 |
| CI 1008 |
| CI-1008 |
| CM14412 |
| CP0100 |
| CS-1247 |
| CTK9A5767 |
| D02716 |
| DB00230 |
| DEA No. 2782 |
| DSSTox_CID_25950 |
| DSSTox_GSID_45950 |
| DSSTox_RID_81246 |
| DTXSID1045950 |
| EN300-92104 |
| FT-0080911 |
| GTPL5484 |
| Hexanoic acid, 3-(aminomethyl)-5-ethyl-, (3S)- |
| Hexanoic acid, 3-(aminomethyl)-5-methyl-, (3S)- |
| Hexanoic acid, 3-(aminomethyl)-5-methyl-, (S)- |
| HMS3715J16 |
| HSDB 7530 |
| HY-17414 |
| KB-01630 |
| KS-00000AF5 |
| KS-5378 |
| KSC005O6P |
| LS-75191 |
| Lyrica (TN) |
| MFCD00917044 |
| NCGC00095186-01 |
| NCGC00346738-01 |
| Nervalin |
| PD 144723 |
| PD-144723 |
| Pregabalin |
| Pregabalin (JAN/USAN/INN) |
| Pregabalin [USAN:INN:BAN:JAN] |
| Pregabalin [USAN] |
| Pregabalin 1.0 mg/ml in Methanol |
| Pregabalin, >=97% (NMR) |
| Pregabalin, EuropePharmacopoeia (EP) Reference Standard |
| Pregablin |
| S-(+)-3-isobutylgaba |
| SC-11867 |
| SCHEMBL8227 |
| SR-01000942257 |
| SR-01000942257-2 |
| ST2408318 |
| TL8001062 |
| TOS-BB-0910 |
| Tox21_111475 |
| UNII-55JG375S6M |
| W-5218 |
| Z2757554242 |
| ZINC5152 |
US Patents and Regulatory Information for LYRICA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | LYRICA CR | pregabalin | TABLET, EXTENDED RELEASE;ORAL | 209501-002 | Oct 11, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Pf Prism Cv | LYRICA | pregabalin | CAPSULE;ORAL | 021446-006 | Dec 30, 2004 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Pf Prism Cv | LYRICA | pregabalin | CAPSULE;ORAL | 021446-005 | Dec 30, 2004 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for LYRICA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pf Prism Cv | LYRICA | pregabalin | CAPSULE;ORAL | 021446-003 | Dec 30, 2004 | ➤ Sign Up | ➤ Sign Up |
| Pf Prism Cv | LYRICA | pregabalin | CAPSULE;ORAL | 021446-001 | Dec 30, 2004 | ➤ Sign Up | ➤ Sign Up |
| Pf Prism Cv | LYRICA | pregabalin | CAPSULE;ORAL | 021446-002 | Dec 30, 2004 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for LYRICA
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Tablets | 330 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Extended-release Tablets | 82.5 mg and 165 mg | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Oral Solution | 20 mg/mL | ➤ Subscribe | ➤ Sign Up |
| ➤ Subscribe | Capsules | 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg | ➤ Subscribe | ➤ Sign Up |
International Patents for LYRICA
Supplementary Protection Certificates for LYRICA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0641330 | SPC016/2004 | Ireland | ➤ Sign Up | SPC016/2004: 20050803, EXPIRES: 20180517 |
| 0641330 | CA 2004 00036 | Denmark | ➤ Sign Up | |
| 0641330 | 27/2004 | Austria | ➤ Sign Up | PRODUCT NAME: PREGABALIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/04/279/001 - EU/1/04/279/025 20040706 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
